All In Biotech

Drug Trial Radar · NCT07428473

A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

A Phase 1 Open-Label Single Ascending Dose (Part 1) and Single or Multi-Dose Expansion (Part 2) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Dec 30, 2028

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Monash UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Scribe Therapeutics Inc.
First posted
Feb 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene. STX-1150 comprises an mRNA and guide RNA (gRNA) delivered via lipid nanoparticles (LNP) for intravenous infusion. The mRNA produces a protein that switches off the PCSK9 gene expression without altering the DNA sequence. This process leverages natural mechanisms that regulate gene activity. The study will enroll up to 64 participants with elevated LDL-C across sites in Australia and New Zealand. The follow-up period will be up to 1- year post-treatment.

Conditions

  • Elevated LDL-C and High Cholesterol

Interventions

  • STX-1150Drug

    Drug: STX-1150 is an investigational product designed to epigenetically silence the PCSK9 gene. Epigenome modulation offers a way to silence genes without changing their underlying DNA sequence.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 52 from administration of STX-1150
  2. Incidence and Severity of Serious Adverse Events (SAEs)Time frame: Up to Week 52 from administration of STX-1150
  3. Incidence and Severity of Adverse Events of Special Interest (AESI)Time frame: Up to Week 52 from administration of STX-1150

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Monash Health/ Victorian Heart Hospital (VHH)

    Clayton, Victoria, Australia · Recruiting

  • Aotearoa Clinical Trials/Middlemore Hospital

    Papatoetoe, Auckland, New Zealand · Recruiting

  • New Zealand Clinical Research (NZCR)

    Christchurch, Christchurch, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.